Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

Microcap produces anti-aging protein from encapsulated cells

Avaí Bio, in collaboration with Austrianova, is set to unveil findings from their α-Klotho anti-aging program at the upcoming Second Annual Klotho Conference in September 2026. This initiative, conducted through their joint venture Klothonova, leverages Austrianova’s Cell-in-a-Box encapsulation platform to deliver genetically modified cells that overexpress α-Klotho. This innovative approach aims to sustainably restore circulating α-Klotho levels, which are known to decline with age and have been associated with various age-related conditions, including cardiovascular, kidney, and cognitive dysfunction.

The significance of this program lies in its potential to address the decline of circulating α-Klotho—a biomarker linked to aging and healthspan. Research indicates that maintaining or restoring α-Klotho levels could mitigate the effects of aging on multiple organ systems, thereby improving overall health outcomes. The projected growth of the global longevity biotech market, estimated to increase from $9.86 billion in 2025 to approximately $29.7 billion by 2034, underscores the therapeutic potential of cellular therapies and gene-based interventions, positioning this research at the forefront of the aging biology field.

The key takeaway from this development is its potential to shift current research paradigms regarding age-related therapies. By focusing on the restoration of α-Klotho levels, this program could pave the way for new treatment strategies that not only target specific diseases but also promote a broader approach to enhancing healthspan. As the field moves toward more integrated solutions for age-related conditions, the findings presented at the Klotho Conference may influence future drug development timelines and strategies, emphasizing the importance of cellular and gene therapies in longevity research.

Source: longevity.technology